Taro Pharma (TARO) reported Q4 EPS of $0.19, $0.68 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $163.12 million.
Taro Pharma (TARO) reported Q4 EPS of $0.19, $0.68 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $163.12 million.